PMID- 30084689
OWN - NLM
STAT- MEDLINE
DCOM- 20190228
LR  - 20210204
IS  - 1530-891X (Print)
IS  - 1530-891X (Linking)
VI  - 24
IP  - 10
DP  - 2018 Oct 2
TI  - DEXAMETHASONE STRESS TEST: A PILOT CLINICAL STUDY FOR IDENTIFICATION OF 
      INDIVIDUALS HIGHLY PRONE TO DEVELOP TYPE 2 DIABETES.
PG  - 894-899
LID - 10.4158/EP-2018-0188 [doi]
AB  - OBJECTIVE: We examined whether the "Dexamethasone Stress Test" exhibits the 
      requisite high predictive ability to identify individuals highly prone to develop 
      type 2 diabetes mellitus (T2DM). METHODS: Seven years ago, we administered an 
      oral glucose tolerance test (OGTT) to 33 individuals without T2DM and repeated 
      the OGTT 24 hours after a single oral dose of 8 mg dexamethasone (Dex); all 
      participants had a first-degree relative with T2DM, and close to half had 
      prediabetes. We calculated receiver operating characteristic (ROC) curves for all 
      parameters derived from the OGTT before and after Dex in individuals who 
      subsequently developed diabetes compared to individuals who did not. RESULTS: At 
      7 years of follow-up, 9 individuals had developed T2DM, while 24 remained without 
      diabetes. None of the OGTT-derived parameters before administration of Dex had an 
      area under the ROC curve of >0.8. However, 24 hours after Dex, three parameters, 
      including fasting plasma insulin, homeostatic model assessment-insulin 
      resistance, and 2-hour plasma glucose level, exhibited areas under the ROC curves 
      of 0.84, 0.86, and 0.92, respectively. CONCLUSION: The Dexamethasone Stress Test 
      appears to be a good to excellent test in identifying individuals highly prone to 
      develop T2DM. ABBREVIATIONS: AUC = area under the curve; Dex = dexamethasone; 
      HOMA-IR = homeostatic model assessment-insulin resistance; NGT = normal glucose 
      tolerance; OGTT = oral glucose tolerance test; PreDiab = prediabetes; ROC = 
      receiver operating characteristic; T2DM = type 2 diabetes mellitus.
FAU - Taheri, Nader
AU  - Taheri N
FAU - Aminorroaya, Ashraf
AU  - Aminorroaya A
FAU - Ismail-Beigi, Faramarz
AU  - Ismail-Beigi F
FAU - Amini, Massoud
AU  - Amini M
LA  - eng
PT  - Clinical Study
PT  - Journal Article
DEP - 20180807
PL  - United States
TA  - Endocr Pract
JT  - Endocrine practice : official journal of the American College of Endocrinology 
      and the American Association of Clinical Endocrinologists
JID - 9607439
RN  - 0 (Insulin)
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
MH  - Adult
MH  - Dexamethasone/*therapeutic use
MH  - Diabetes Mellitus, Type 2/*diagnosis/pathology
MH  - *Diagnostic Techniques, Endocrine
MH  - Disease Progression
MH  - Early Diagnosis
MH  - Female
MH  - Follow-Up Studies
MH  - Gluconeogenesis/drug effects
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Insulin/metabolism
MH  - Insulin Resistance
MH  - Liver/drug effects/metabolism
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Prediabetic State/*diagnosis/metabolism/pathology
MH  - Predictive Value of Tests
MH  - Proof of Concept Study
MH  - Risk Factors
EDAT- 2018/08/08 06:00
MHDA- 2019/03/01 06:00
CRDT- 2018/08/08 06:00
PHST- 2018/08/08 06:00 [pubmed]
PHST- 2019/03/01 06:00 [medline]
PHST- 2018/08/08 06:00 [entrez]
AID - S1530-891X(20)35454-9 [pii]
AID - 10.4158/EP-2018-0188 [doi]
PST - ppublish
SO  - Endocr Pract. 2018 Oct 2;24(10):894-899. doi: 10.4158/EP-2018-0188. Epub 2018 Aug 
      7.